AbbVie Inc. (ABBV) Releases FY14 Earnings Guidance
AbbVie Inc. (NASDAQ:ABBV) updated its FY14 earnings guidance on Friday. The company provided EPS guidance of $3.00-3.10 for the period, compared to the Thomson Reuters consensus EPS estimate of $3.16, Stock Ratings News reports. The company issued revenue guidance of ~$19 billion, compared to the consensus revenue estimate of $19.12 billion.
A number of research firms have recently commented on ABBV. Analysts at BMO Capital Markets cut their price target on shares of AbbVie from $58.00 to $57.00 in a research note to investors on Tuesday. On a related note, analysts at Jefferies Group raised their price target on shares of AbbVie from $67.00 to $68.00 in a research note to investors on Thursday, January 9th. They now have a buy rating on the stock. Finally, analysts at UBS AG reiterated a neutral rating on shares of AbbVie in a research note to investors on Monday, January 6th. They now have a $56.00 price target on the stock, up previously from $46.00. Four research analysts have rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the company’s stock. AbbVie has an average rating of Buy and an average price target of $55.88.
Shares of AbbVie Inc. (NASDAQ:ABBV) traded up 2.50% on Friday, hitting $49.52. The stock had a trading volume of 4,969,205 shares. AbbVie Inc. has a 52-week low of $35.01 and a 52-week high of $54.78. The stock has a 50-day moving average of $50.98 and a 200-day moving average of $47.40. The company has a market cap of $78.638 billion and a P/E ratio of 17.03.
AbbVie (NASDAQ:ABBV) last released its earnings data on Friday, January 31st. The company reported $0.82 earnings per share for the quarter, meeting the analysts’ consensus estimate of $0.82. The company had revenue of $5.11 billion for the quarter, compared to the consensus estimate of $5.10 billion. The company’s revenue for the quarter was down 1.8% on a year-over-year basis. Analysts expect that AbbVie Inc. will post $3.14 EPS for the current fiscal year.
AbbVie Inc (NASDAQ:ABBV) is a research-based pharmaceuticals company.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.